MAPRE3

Across TCGA pan-cancer cohorts, MAPRE3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPRE3 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAPRE3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAPRE3 expression acts as an unfavorable survival marker.

HNSC, OV, and STAD are the cancer types where MAPRE3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.086	0.743	<.001	30	view →
OV	DFS	Median	II,III,IV	0.218	0.542	.004	18	view →
STAD	DFS	Median	All	0.205	0.658	.004	18	view →
LUAD	OS	Median	All	0.338	0.834	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAPRE3–HNSC (OS)

Open the HNSC breakdown →